What is the problem with Invokana?
Some of the top warnings associated with Invokana (canagliflozin) treatment include the risk of amputation of a lower limb, dehydration and low blood pressure, genital yeast infections in men and women, serious allergic reactions and kidney problems.
Is Invokana being taken off the market?
Is Invokana being taken off the market? Currently, Invokana is still on the market. The FDA did in 2017 regarding the increased risk of lower limb amputations in patients with established cardiovascular disease.
Is Invokana bad for kidneys?
Taking Invokana can increase your risk of kidney damage. Symptoms of kidney damage can include: urinating less often than normal. swelling in your legs, ankles, or feet.
Is Invokana hard on kidneys?
How much is the Invokana lawsuit worth?
More than 50,000 people who had a heart attack while taking Avandia filed a class action lawsuit. The lawsuits were settled in 2010 for more than $750 million.
Is there a substitute drug for Invokana?
Multiple brand-name drugs are on the market that are similar to Invokana. Just like Invokana, Farxiga and Jardiance are two SGLT2 inhibitors used to control blood sugar in those with type 2 diabetes.
How much support do I get for Invokana?
Support for patients using commercial or private insurance: Eligible commercial patients pay $0 per month for INVOKANA®, subject to monthly program benefit limits. There is no limit to this benefit for the first month of treatment, and then $200 limit for each month thereafter. There is a $3,000 maximum program benefit per calendar year.
How much does Janssen carepath pay for Invokana?
Janssen CarePath can help you find out what affordability assistance may be available for your patients taking INVOKANA®: Support for patients using commercial or private insurance: Eligible commercial patients pay $0 per month for INVOKANA®, subject to monthly program benefit limits.
Is there a free 30 day Invokana trial?
A free 30-day trial offer is available for eligible patients to help them become familiar with INVOKANA®. At the conclusion of the program, you and your patient decide if it is appropriate to continue treatment. Subject to 1 (one) use per product, per lifetime. Terms expire at the end of each calendar year and may change.